Lv6
3090 积分 2023-05-22 加入
AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction–associated steatotic liver disease
1个月前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease
2个月前
已完结
Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study
2个月前
已关闭
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
2个月前
已完结
Endothelins in cardiovascular biology and therapeutics
2个月前
已完结
Steatotic liver disease
2个月前
已完结
JNK at the helm: decoding obesity-driven insulin resistance
2个月前
已完结
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes
3个月前
已完结
Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial
3个月前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
3个月前
已完结
皖公网安备34019202002308
